BioCentury | Sep 15, 2017
Company News

Gene therapy company Rocket finds public path

...therapies unit at Novartis AG (NYSE:NVS; SIX:NOVN). In January, Inotek said its lead candidate trabodenoson (INO-8875...
...to treat primary open-angle glaucoma or ocular hypertension (see BioCentury, Jan. 6 ). In July, trabodenoson...
...Inotek Pharmaceuticals Corp. (NASDAQ:ITEK), Lexington, Mass. Rocket Pharmaceuticals Ltd., New York, N.Y. Business: Gene/Cell therapy Chris Lieu INO-8875 trabodenoson Inotek...
BioCentury | Sep 12, 2017
Company News

Gene therapy company Rocket finds public path

...therapies unit at Novartis AG (NYSE:NVS; SIX:NOVN). In January, Inotek said its lead candidate trabodenoson (INO-8875...
...treat primary open-angle glaucoma or ocular hypertension (see BioCentury Extra, Jan. 3) . In July, trabodenoson...
...announced the merger after market close, and lost $0.10 (10%) to $0.95 in after-hours trading. Chris Lieu INO-8875 trabodenoson Inotek...
BioCentury | Apr 7, 2017
Finance

Fade to black

...the Phase II EffiKIR trial to treat elderly patients with AML Inotek Pharmaceuticals Corp. (NASDAQ:ITEK) Trabodenoson...
BioCentury | Jan 6, 2017
Clinical News

Trabodenoson: Ph III MATrX-1 data

...open-angle glaucoma or ocular hypertension showed that once-daily 3% and 6% and twice-daily 4.5% topical trabodenoson...
...8 AM, 10 AM, 12 PM and 4 PM. Inotek said that no dose of trabodenoson...
...of trabodenoson and latanoprost mid-year. Inotek Pharmaceuticals Corp. (NASDAQ:ITEK), Lexington, Mass. Product: Trabodenoson (INO-8875) (formerly PJ-875...
BioCentury | Jan 3, 2017
Clinical News

Inotek plummets on Phase III glaucoma miss

...Inotek Pharmaceuticals Corp. (NASDAQ:ITEK) sank $4.35 (71%) to $1.75 after it said trabodenoson ( INO-8875...
...four times of day on days 28, 42 and 84. None of the study's three trabodenoson...
...Trabodenoson is a selective adenosine A1 receptor (ADORA1) agonist. The company said there were no trabodenoson-related...
BioCentury | Dec 31, 2016
Finance

Delivering takeouts

...or refractory chronic lymphocytic leukemia (CLL) Ph III DUO data 1H17 Inotek Pharmaceuticals Corp. (NASDAQ:ITEK) Trabodenoson...
BioCentury | Oct 3, 2016
Finance

ASH and others

...NASDAQ:INNL) XaraColl bupivacaine collagen sponge Manage postoperative pain Submit NDA 4Q16 Inotek Pharmaceuticals Corp. (NASDAQ:ITEK) Trabodenoson...
BioCentury | Sep 5, 2016
Clinical News

Trabodenoson: Completed Phase III enrollment

...enrollment of about 335 patients in the double-blind, U.S. Phase III MATrX-1 trial comparing topical trabodenoson...
...or 0.5% timolol in both eyes for 12 weeks. Patients will receive 3% or 6% trabodenoson...
...dose twice daily. Inotek Pharmaceuticals Corp. (NASDAQ:ITEK), Lexington, Mass. Product: Trabodenoson ( INO-8875 ) (formerly PJ-875...
BioCentury | Jul 25, 2016
Clinical News

Trabodenoson/latanoprost: Phase II started

...Inotek began a double-blind, placebo-controlled, U.S. Phase II trial to compare once-daily trabodenoson/latanoprost given as a...
...IOP of 25-34 mmHg. Patients will receive 3% trabodenoson/0.005% latanoprost; 6% trabodenoson/0.005% latanoprost; or 6% trabodenoson/0.025%...
...latanoprost; 6% trabodenoson/0.005% latanoprost; or 6% trabodenoson/0.025% latanoprost. Inotek Pharmaceuticals Corp. (NASDAQ:ITEK), Lexington, Mass. Product: Trabodenoson/latanoprost...
BioCentury | Jul 11, 2016
Finance

Rethinking risk

...furoate/umeclidinium/vilanterol Chronic obstructive pulmonary disease (COPD) Submit MAA and NDA YE16 Inotek Pharmaceuticals Corp. (NASDAQ:ITEK) Trabodenoson...
Items per page:
1 - 10 of 28